A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

NCT05929066 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the medication retatrutide in adults who have obesity or overweight to see how it affects their body weight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 2,335 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-07 · est. completion 2026-05

Where 134 sites · Australia, Brazil, Canada, Hungary, India, Mexico, Poland, Puerto Rico, Romania, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT05929066 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05929066 ↗